Scarica l'app Stockscreener
398.29
0.28%
-1.11
Dopo l'orario di chiusura:
398.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Gene Therapy Market to Reach US$ 35.91 Billion by 2033 | CAGR 23.1% - openPR.com
Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterJuly 2025 Retail & Technical Pattern Based Buy Signals - ulpravda.ru
Is Alnylam Pharmaceuticals Inc. (DUL) stock testing key supportEarnings Risk Summary & Capital Efficient Trade Techniques - ulpravda.ru
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As It Previews New Five Year Plan And Revenue Outlook - simplywall.st
Is Alnylam Pharmaceuticals Inc. stock safe for conservative investorsWeekly Trend Summary & Reliable Volume Spike Alerts - ulpravda.ru
Europe Gene Therapy Market to hit US$ 8,780.77 Million by 2033 | - openPR.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Seems To Use Debt Quite Sensibly - Yahoo Finance
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical - GlobeNewswire Inc.
Will Alnylam Pharmaceuticals Inc. stock remain a Wall Street favorite2026 world cup usa national team group stage young talents build up play winner prediction statistical analysis - ulpravda.ru
Bernstein lowers Alnylam stock price target to $491 on slowing Amvuttra sales - Investing.com UK
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Fair Valuation - Chartmill
Nucleic Acid Therapeutics Market to Reach US$ 14.42 Billion - openPR.com
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Generali Asset Management SPA SGR Has $1.48 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Western Financial Corp CA Invests $1.24 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500 - FinancialContent
Aug Closing: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerJuly 2025 Action & Risk Controlled Swing Alerts - moha.gov.vn
U.S. Transthyretin Amyloidosis Treatment Market Insights - openPR.com
Cardiovascular Biologics Market to Reach USD 4.23 Billion - openPR.com
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Cwm LLC - MarketBeat
Japan Gene Therapy Market is expected to reach US$ 904.94 Million - openPR.com
Alnylam plans $250M investment in Norton manufacturing facility, US - MSN
Alnylam Pharmaceuticals (STU:DUL) EV-to-OCF : 207.04 (As of Dec. 28, 2025) - GuruFocus
Highland Capital Management LLC Buys Shares of 4,569 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Massachusetts lands rare manufacturing wins from Moderna and Alnylam amid tariff push - The Business Journals
Brighton Jones LLC Acquires 3,909 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion - simplywall.st
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23) - ts2.tech
Here’s why Alnylam Pharmaceuticals (ALNY) surged in Q3 - MSN
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook - ts2.tech
Alnylam Pharmaceuticals, Inc.(NasdaqGS: ALNY) added to NASDAQ-100 Index - marketscreener.com
RNAi (RNA Interference) Technology Market to Reach US$ 6.63 - openPR.com
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open - ts2.tech
Bear Alert: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerQuarterly Risk Review & Low Risk Profit Maximizing Plans - Улправда
118,800 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Congress Asset Management Co. - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
PeptiDream (TSE:4587): Assessing Valuation After New IL-17 Oral Candidate and Alnylam siRNA Milestone - Yahoo Finance
Market Moves: Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterQuarterly Profit Review & AI Driven Price Forecasts - ulpravda.ru
Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025 - ts2.tech
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by U.S. Capital Wealth Advisors LLC - MarketBeat
What PeptiDream (TSE:4587)'s New Oral IL-17 Program and RNAi Milestone Mean For Shareholders - Yahoo! Finance Canada
Is Alnylam Pharmaceuticals Inc. stock recession proofJuly 2025 Trends & AI Powered Market Entry Ideas - Улправда
Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open - ts2.tech
Portfolio Recap: Will Alnylam Pharmaceuticals Inc. stock remain a Wall Street favoriteJuly 2025 Trends & Accurate Entry and Exit Point Alerts - ulpravda.ru
Why Alnylam Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 - Finviz
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive post correctionMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
Will Alnylam Pharmaceuticals Inc. stock attract more institutional investorsOil Prices & Verified Momentum Stock Watchlist - DonanımHaber
How buybacks impact Alnylam Pharmaceuticals Inc. stock valueJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - DonanımHaber
Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 - Insider Monkey
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Alnylam’s Manufacturing Expansion and Extra-Hepatic RNAi Delivery Could Be A Game Changer For Alnylam Pharmaceuticals (ALNY) - Yahoo Finance
Is It Too Late to Consider Alnylam After a 67.8% Surge in 2025? - Yahoo Finance
Alnylam Announces 250M Investment To Expand US Manufacturing Capacity In Massachusetts For RNAi Therapeutics - Bioprocess Online
Demand prompts Alnylam’s $250 million manufacturing expansion - The Pharma Letter
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues - BioSpace
Alnylam plans $250m investment in Norton manufacturing facility, US - Yahoo Finance
Alnylam to invest $250 million in expanding RNA drug manufacturing By Investing.com - Investing.com Nigeria
0.89%
3.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):